Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
olopatadine hydrochloride nasal spray for seasonal allergic rhinitis (Phase III, China)
CTR20260022Phase 3Active
- Sponsor
- Yingkerui (Hengqin) Drug Research Institute
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing Olopatadine hydrochloride nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Change rate in mean total nasal symptom score (TNSS) from baseline at Day 14. Started Apr 2026; status: active.
02
Drugs
olopatadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20260022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260022.